{{Drugbox
| verifiedrevid = 443421622
| IUPAC_name = (''RS'')-[2-(3,4-dimethoxyphenyl)ethyl][2-hydroxy-3-(3-methylphenoxy)propyl]amine
| image = Bevantolol.png
| width = 240px
| chirality = [[Racemic mixture]]
| drug_name = 
<!--Clinical data-->
| tradename =  
| Drugs.com = {{drugs.com|international|bevantolol}}
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category =  
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C -->
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_status = unapproved, never marketed
| routes_of_administration = Oral
<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =
<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 59170-23-9
| ATC_prefix = C07
| ATC_suffix = AB06
| ATC_supplemental =  
| PubChem = 2372
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB01295
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 2282
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 34ZXW6ZV21
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 238698
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 314010
<!--Chemical data-->
| chemical_formula =
| C=20 | H=27
| N=1 | O=4
| molecular_weight = 345.43 g/mol
| smiles = O(c1ccc(cc1OC)CCNCC(O)COc2cc(ccc2)C)C
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C20H27NO4/c1-15-5-4-6-18(11-15)25-14-17(22)13-21-10-9-16-7-8-19(23-2)20(12-16)24-3/h4-8,11-12,17,21-22H,9-10,13-14H2,1-3H3
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = HXLAFSUPPDYFEO-UHFFFAOYSA-N
}}

'''Bevantolol''' ([[International Nonproprietary Name|INN]]) was a drug candidate for angina and hypertension that acted as both a [[beta blocker]] and a [[calcium channel blocker]].<ref>{{cite journal|last1=Frishman|first1=WH|last2=Goldberg|first2=RJ|last3=Benfield|first3=P|title=Bevantolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and angina pectoris.|journal=Drugs|date=January 1988|volume=35|issue=1|pages=1–21|pmid=2894292}}</ref><ref>{{cite journal|last1=Vaughan Williams|first1=EM|title=Bevantolol: a beta-1 adrenoceptor antagonist with unique additional actions.|journal=Journal of clinical pharmacology|date=July 1987|volume=27|issue=7|pages=450–60|pmid=2888789}}</ref>  It was [[drug discovery|discovered]] and [[drug development|developed]] by [[Warner-Lambert]]<ref>{{cite book|last1=McPherson|first1=Edwin M.|title=Pharmaceutical Manufacturing Encyclopedia.|date=2007|publisher=Elsevier|location=Burlington|isbn=9780815518563|pages=618–619|edition=3rd|url=https://books.google.com/books?id=_J2ti4EkYpkC&pg=PA618}}</ref> but in January 1989 the company announced that it had withdrawn the [[New Drug Application]]; the company's chairman said: "Who needs the 30th beta blocker?"<ref>{{cite news|title=Warner-Lambert Pipeline Narrowed to 40 Active Research Compounds|url=https://pink.pharmamedtechbi.com/PS015015/WARNERLAMBERT-PIPELINE-NARROWED-TO-40-ACTIVE-RESEARCH-COMPOUNDS-ACCUPRIL-QUINAPRIL-NDA-SUBMITTED-JAN-25-80-MIL-BUDGETTED-FOR-CV-WORK-IN-1989|work=Pink Sheet|date=30 January 1989}}</ref> As of 2016 it wasn't marketed in the US, UK, or Europe and the authors of a Cochrane review could find no product monograph for it.<ref>{{cite journal|last1=Wong|first1=GW|last2=Boyda|first2=HN|last3=Wright|first3=JM|title=Blood pressure lowering efficacy of beta-1 selective beta blockers for primary hypertension.|journal=The Cochrane database of systematic reviews|date=10 March 2016|volume=3|pages=CD007451|pmid=26961574}}</ref>

== References ==
{{Reflist|2}}

{{beta blockers}}

[[Category:Beta blockers]]
[[Category:O-Methylated phenols]]
[[Category:Alcohols]]
[[Category:Amines]]
[[Category:Abandoned drugs]]


{{Amine-stub}}
{{cardiovascular-drug-stub}}